The 3rd European Cancer and Oncology Congress, scheduled for September 14–15, 2026 in London, U.K, will be a premier forum for advancing cancer science and clinical care. Designed to foster collaboration and innovation, the event will convene oncologists, scientists, healthcare professionals, nurses, and researchers from across Europe and beyond to exchange knowledge, discuss new findings, and spotlight transformative developments in oncology.
Attendees can look forward to a rich and engaging program featuring high-impact keynote sessions from world-renowned experts, thought-provoking symposia, interactive workshops, and research poster showcases. The congress will delve into critical areas including precision oncology, immunotherapy, emerging treatment strategies, survivorship, palliative and supportive care, and the integration of digital tools and AI into oncology practice. Set against the stunning backdrop of London, this event offers an inspiring environment to connect, learn, and drive progress in cancer care.
Abstract Submission Deadline: December 15, 2025
Early Bird Registration: December 16, 2025
Mid Term Registration: February 27, 2026
Final/Onsite Registration: September 14, 2026
GermanOncology
Germany
Phoenicia Medical Centre PMC
Lebanon
Aakash Healthcare Superspeciality Hospital
India
N.N. Petrov National Medical Research Center of Oncology
Russia
About Oncotarget
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking diff erent fi elds of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative; 2018-2022) and Dimensions (Digital Science).
Scope
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural editorial, Introducing Oncotarget.
C2P Forum is pleased to announce the successful completion of the 2nd European Meeting on Cancer and Oncology, held on November 03-04, in Prague, Czech Republic.
The conference, themed “Exploring New Horizons in Oncology and Cancer Research,” concluded with great success.
We extend our sincere gratitude to the esteemed scientists, distinguished researchers, students and professionals from universities, research institutions, companies, and laboratories worldwide who contributed their latest insights and expertise in the field of Cancer and Oncology.
The conference featured a dynamic program, including keynote addresses, oral presentations, poster sessions, video presentation and E-Poster Presentations. The event was marked by significant engagement and outstanding contributions, and we are delighted to share some of the key highlights presented during the sessions:
• Paola Dal Cin, Brigham and Women’s Hospital & Harvard Medical School, USA
• Genia Burchall, Central Queensland University, Australia
• Avigdor Scherz, The Weizmann Institute of Science, Israel
• Giacomina Brunetti, University of Bari Aldo Moro, Italy
• Silvia Scaglione, National Research Council (CNR), Italy
• Amal Assef Nasser, Phoenicia Medical Center (PMC), Lebanon
• Folinas Konstantinos, 251 Airforce General Hospital, Greece
• Martyna Pytlarz, Technical University of Denmark, Denmark
• Ch’ng You Qun, University Hospitals of Leicester NHS Trust, UK
• Laura Cerchia, Institute of Endotypes in Oncology, Metabolism and Immunology “G. Salvatore”- National Research Council (IEOMI-CNR), Italy
• Ella Fernandes, King's College London NHS Trust, UK
• Monica Fedele, Institute of Endotypes in Oncology, Metabolism and Immunology “G. Salvatore”- National Research Council (IEOMI-CNR), Italy
• Elena-Mihaela Vrabie, Fundeni Clinical Institute & Carol Davila University of Medicine and Pharmacy, Romania
• Dan Cacsire Castillo-Tong, Medical University of Vienna, Austria
• Daniel Tippner, Martin Luther University Halle-Wittenberg, Germany
• Mónica G Mendoza-Rodríguez, Universidad Nacional Autónoma de México, México
• Mike Alexander Celis Rodríguez, Universidad Industrial de Santander, Colombia
• Morsal Sabihi, University Medical Center Hamburg-Eppendorf, Germany
• Amira Mahmoud Ali Abdallah, Sheikh Shakhbout Medical City, UAE
• Ferhat Bostanci, Istanbul Sabahattin Zaim University & Yıldız Technical University, Turkey
• José Carlos Jaime-Pérez, Universidad Autónoma de Nuevo León, México
• Andrada Nemesis Crișan & Roxana Elena Sicoe, Galaxy Medical Center, Romania
• Rana Ajami, Ziv Medical Center, Israel
• Elena Bukovetzky & Mona Nassar, Ziv Medical Center, Israel
• Shivani Golem, University of Kansas Medical Center, USA
• Swapnil Surpur, Wright Center for Graduate Medical Education, USA
• Siqi Hua, Shanghai Jiao Tong University, China
• Ema Ruszova, University Hospital Bulovka, Czech Republic
We would like to express our sincere appreciation to our Session Chairs Paola Dal Cin, Brigham and Women’s Hospital & Harvard Medical School, USA, Folinas Konstantinos, 251 Airforce General Hospital, Greece, & Avigdor Scherz, The Weizmann Institute of Science, Israel
Building on the success of the Cancer Congress 2025, we are pleased to announce our upcoming event, 3rd European Cancer and Oncology Congress on September 14-15, 2026 in London, UK
More info: https://cancer.c2pforum.com/
Huge thanks to all the delegates! Your energy and involvement made this event a big success!
Mark your calendars and set your reminders.
Hope to meet you again in London, UK!!